Document is current
Any future updates will be listed below
-
Authors
Yoshida, Hayao https://orcid.org/0009-0005-0155-9177
Murakami, Takaaki https://orcid.org/0000-0003-3844-1138
Miyake, Kanae Kawai
Shimizu, Yoichi
Itagaki, Koji
Sakaki, Kentaro
Otani, Daisuke
Fujimoto, Hiroyuki https://orcid.org/0009-0009-7084-1423
Yabe, Daisuke https://orcid.org/0000-0002-5334-7687
Inagaki, Nobuya
Nakamoto, Yuji
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (24K02359)
Moriya Scholarship Foundation (Moriya Scholarship Foundation)
Manpei Suzuki Diabetes Foundation (Manpei Suzuki Diabetes Foundation)
Suzuken Memorial Foundation (Suzuken Memorial Foundation)
Japan Foundation of Applied Enzymology (Japan Foundation of Applied Enzymology)
Terumo Health Management Research Foundation (Terumo Health Management Research Foundation)
Advanced Science, Technology & Management Research Institute of KYOTO (Advanced Science, Technology & Management Research Institute of KYOTO)
The Japan Health Foundation (The Japan Health Foundation)
- License Information
-
More Information
Article History
Received: 5 July 2025
Accepted: 4 August 2025
First Online: 21 August 2025
Declarations
:
: The study protocol was approved by The Kyoto University Certified Review Board (Y0074, Registered 1 March 2021). The first subject was enrolled on August 12, 2022. All procedures were conducted in accordance with the Declaration of Helsinki and other relevant ethical guidelines. Written informed consent was obtained from the participant prior to their inclusion in the study.
: NI received joint research grants from Asken Inc., received speaker honoraria from Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., Sumitomo Pharma Co., Ltd., and Mitsubishi Tanabe Pharma Corporation, and received scholarship grants from Mitsubishi Tanabe Pharma Corporation, Sumitomo Pharma Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd. DY received clinically commissioned/joint research grants from Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Terumo Corp., and ARKRAY, Inc. DY also received consulting or speaker fees from Sumitomo Pharma Co., Ltd., Nippon Boehringer Ingelheim Co Ltd., Astellas Pharma Inc., MSD K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Takeda Pharmaceutical Company Limited. TM has received joint research grants from Sumitomo Pharma Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
